Atkins MB - Search Results

1

Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma.

Pal SK, McDermott DF, Atkins MB, Escudier B, Rini BI, Motzer RJ, Fong L, Joseph RW, Oudard S, Ravaud A, Bracarda S, Suárez C, Lam ET, Choueiri TK, Ding B, Quach C, Hashimoto K, Schiff C, Piault-Louis E, Powles T. Pal SK, et al. Among authors: atkins mb. BJU Int. 2020 Jul;126(1):73-82. doi: 10.1111/bju.15058. Epub 2020 Apr 24. BJU Int. 2020. PMID: 32233107 Free PMC article. Clinical Trial.

2

Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma.

Fallick ML, McDermott DF, LaRock D, Long JP, Atkins MB. Fallick ML, et al. Among authors: atkins mb. J Urol. 1997 Nov;158(5):1691-5. doi: 10.1016/s0022-5347(01)64097-7. J Urol. 1997. PMID: 9334580 Clinical Trial.

3

Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.

Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, Clancy M, Atkins MB. Gollob JA, et al. Among authors: atkins mb. Clin Cancer Res. 2000 May;6(5):1678-92. Clin Cancer Res. 2000. PMID: 10815886 Clinical Trial.

4

A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.

McDermott DF, Mier JW, Lawrence DP, van den Brink MR, Clancy MA, Rubin KM, Atkins MB. McDermott DF, et al. Among authors: atkins mb. Clin Cancer Res. 2000 Jun;6(6):2201-8. Clin Cancer Res. 2000. PMID: 10873069 Clinical Trial.

5

A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.

Atkins MB, Gollob JA, Sosman JA, McDermott DF, Tutin L, Sorokin P, Parker RA, Mier JW. Atkins MB, et al. Clin Cancer Res. 2002 Oct;8(10):3075-81. Clin Cancer Res. 2002. PMID: 12374674 Clinical Trial.

6

Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.

Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, Flaherty L, Sosman JA, Logan TF, White R, Weiss GR, Redman BG, Tretter CP, McDermott D, Smith JW, Gordon MS, Margolin KA. Clark JI, et al. Among authors: atkins mb. J Clin Oncol. 2003 Aug 15;21(16):3133-40. doi: 10.1200/JCO.2003.02.014. Epub 2003 Jun 16. J Clin Oncol. 2003. PMID: 12810695 Clinical Trial.

7

Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.

Gollob JA, Veenstra KG, Parker RA, Mier JW, McDermott DF, Clancy D, Tutin L, Koon H, Atkins MB. Gollob JA, et al. Among authors: atkins mb. J Clin Oncol. 2003 Jul 1;21(13):2564-73. doi: 10.1200/JCO.2003.12.119. J Clin Oncol. 2003. PMID: 12829677 Clinical Trial.

8

Application of IL-2 and other cytokines in renal cancer.

McDermott DF, Atkins MB. McDermott DF, et al. Among authors: atkins mb. Expert Opin Biol Ther. 2004 Apr;4(4):455-68. doi: 10.1517/14712598.4.4.455. Expert Opin Biol Ther. 2004. PMID: 15102596 Review.

9

Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses.

Avigan D, Vasir B, Gong J, Borges V, Wu Z, Uhl L, Atkins M, Mier J, McDermott D, Smith T, Giallambardo N, Stone C, Schadt K, Dolgoff J, Tetreault JC, Villarroel M, Kufe D. Avigan D, et al. Clin Cancer Res. 2004 Jul 15;10(14):4699-708. doi: 10.1158/1078-0432.CCR-04-0347. Clin Cancer Res. 2004. PMID: 15269142 Clinical Trial.

10

Innovations and challenges in renal cancer: consensus statement from the first international conference.

Atkins MB, Avigan DE, Bukowski RM, Childs RW, Dutcher JP, Eisen TG, Figlin RA, Finke JH, Flanigan RC, George DJ, Goldberg SN, Gordon MS, Iliopoulos O, Kaelin WG Jr, Linehan WM, Lipton A, Motzer RJ, Novick AC, Stadler WM, Teh BT, Yang JC, King L. Atkins MB, et al. Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6277S-81S. doi: 10.1158/1078-0432.CCR-040720. Clin Cancer Res. 2004. PMID: 15448017 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

474 results

Search Page

Filters